Leishmania vaccines: progress and problems
- Journal Title
- Publication Type
- Journal Article
- Leishmania are protozoan parasites spread by a sandfly insect vector and causing a spectrum of diseases collectively known as leishmaniasis. The disease is a significant health problem in many parts of the world resulting in an estimated 12 million new cases each year. Current treatment is based on chemotherapy, which is difficult to administer, expensive and becoming ineffective due to the emergence of drug resistance. Leishmaniasis is considered one of a few parasitic diseases likely to be controllable by vaccination. The relatively uncomplicated leishmanial life cycle and the fact that recovery from infection renders the host resistant to subsequent infection indicate that a successful vaccine is feasible. Extensive evidence from studies in animal models indicates that solid protection can be achieved by immunisation with protein or DNA vaccines. However, to date no such vaccine is available despite substantial efforts by many laboratories. Advances in our understanding of Leishmania pathogenesis and generation of host protective immunity, together with the completed Leishmania genome sequence open new avenues for vaccine research. The major remaining challenges are the translation of data from animal models to human disease and the transition from the laboratory to the field. This review focuses on advances in anti-leishmania vaccine development over the recent years and examines current problems hampering vaccine development and implementation.
- CAMBRIDGE UNIV PRESS
- AMERICAN CUTANEOUS LEISHMANIASIS; EXPERIMENTAL VISCERAL LEISHMANIASIS; CONFERS PROTECTIVE IMMUNITY; CD4(+) T-CELLS; EXPERIMENTAL MURINE LEISHMANIASIS; MAJOR SURFACE GLYCOPROTEIN; SUSCEPTIBLE BALB/C MICE; DELAYED-TYPE HYPERSENSITIVITY; PRIME-BOOST VACCINATION; P36(LACK) DNA VACCINE
- Publisher's Version
- Rights Notice
- Refer to copyright notice on published article.
Creation Date: 2006-01-01 12:00:00Last Modified: 0001-01-01 12:00:00